Janux Therapeutics, Inc. Common Stock JANX
Analyst Ratings
- Consensus
- Moderate Buy — 10 Buy · 2 Hold · 1 Sell (13 analysts)
- Avg. Price Target
- $36.38 (+185.1% upside)
Key Stats
- Today's Range
- $12.43 – $17.95
- 50-Day Range
- $12.43 – $20.31
- 52-Week Range
- $12.12 – $35.34
- Volume
- 4.85 million shs
- Average Volume
- 907K shs
- Market Cap
- $1.08 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.65%
- Days to Cover
- 1.21
About Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Related Stocks
Compare head-to-head: JANX vs LLY·JANX vs JNJ·JANX vs ABBV·JANX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.